Back to search
Solid Tumors Harboring NTRK Fusion
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Solid Tumors Harboring NTRK Fusion trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Solid Tumors Harboring NTRK Fusion trials you may qualify forThe main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions
Researchers want to learn more about the use of larotrectinib as a real-world treatment for tropomyosin receptor kinase fusion cancer, also called TRK fusion ca…
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolera…
The goal of this clinical trial is to learn about the safety of drug CG001419. It also learn if drug CG001419 works to treat in locally advanced/metastatic adul…
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous S…
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular g…
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders…